Do analysts prefer DRCT or SLGL?

Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 140.97%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Direct Digital 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to DRCT or SLGL?

In the previous week, Sol-Gel Technologies had 14 more articles in the media than Direct Digital. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 3 mentions for Direct Digital. Direct Digital's average media sentiment score of 1.16 beat Sol-Gel Technologies' score of 0.90 indicating that Direct Digital is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Direct Digital 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLGL or AMPH?

In the previous week, Sol-Gel Technologies had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 6 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.08 beat Sol-Gel Technologies' score of 0.90 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLGL or REPL?

In the previous week, Sol-Gel Technologies had 14 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.95 beat Sol-Gel Technologies' score of 0.90 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLGL or ESPR?

In the previous week, Sol-Gel Technologies had 16 more articles in the media than Esperion Therapeutics. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 1 mentions for Esperion Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.90 beat Esperion Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sol-Gel Technologies (SLGL) Competitors

$81.96 +1.41 (+1.75%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$82.66 +0.70 (+0.85%)

As of 07/24/2026 07:34 PM Eastern

Compare

SLGL vs. DRCT, TRAW, AMPH, REPL, and ESPR

Should you buy Sol-Gel Technologies stock or one of its competitors? MarketBeat compares Sol-Gel Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sol-Gel Technologies include Direct Digital (DRCT), Traws Pharma (TRAW), Amphastar Pharmaceuticals (AMPH), Replimune Group (REPL), and Esperion Therapeutics (ESPR).

How does Sol-Gel Technologies compare to Direct Digital?

Direct Digital (NASDAQ:DRCT) and Sol-Gel Technologies (NASDAQ:SLGL) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

4.0% of Direct Digital shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 25.6% of Direct Digital shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 140.97%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Direct Digital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sol-Gel Technologies has lower revenue, but higher earnings than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Direct Digital	$34.69M	0.05	-$18.95M	-$201.62	N/A
Sol-Gel Technologies	$19.39M	11.88	-$6.13M	-$0.34	N/A

In the previous week, Sol-Gel Technologies had 14 more articles in the media than Direct Digital. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 3 mentions for Direct Digital. Direct Digital's average media sentiment score of 1.16 beat Sol-Gel Technologies' score of 0.90 indicating that Direct Digital is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Direct Digital	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies has a net margin of -5.66% compared to Direct Digital's net margin of -65.75%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Direct Digital	-65.75%	N/A	-59.57%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Direct Digital has a beta of 5.32, indicating that its stock price is 432% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Summary

Sol-Gel Technologies beats Direct Digital on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Sol-Gel Technologies had 16 more articles in the media than Traws Pharma. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.89 beat Sol-Gel Technologies' score of 0.90 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
Sol-Gel Technologies	Positive

Traws Pharma currently has a consensus target price of $1.00, suggesting a potential upside of 104.88%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 140.97%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 7.6% of Traws Pharma shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Traws Pharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Traws Pharma has higher earnings, but lower revenue than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.65	$9.17M	-$1.69	N/A
Sol-Gel Technologies	$19.39M	11.88	-$6.13M	-$0.34	N/A

Summary

Sol-Gel Technologies beats Traws Pharma on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Amphastar Pharmaceuticals?

Sol-Gel Technologies (NASDAQ:SLGL) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Sol-Gel Technologies' net margin of -5.66%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Amphastar Pharmaceuticals has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	11.88	-$6.13M	-$0.34	N/A
Amphastar Pharmaceuticals	$719.89M	1.15	$98.09M	$1.66	11.28

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 140.97%. Amphastar Pharmaceuticals has a consensus target price of $22.00, indicating a potential upside of 17.52%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Sol-Gel Technologies is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Sol-Gel Technologies had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 6 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.08 beat Sol-Gel Technologies' score of 0.90 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Sol-Gel Technologies on 9 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Replimune Group?

Sol-Gel Technologies (NASDAQ:SLGL) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Sol-Gel Technologies had 14 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.95 beat Sol-Gel Technologies' score of 0.90 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 140.97%. Replimune Group has a consensus target price of $8.86, indicating a potential downside of 8.69%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Sol-Gel Technologies is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Replimune Group	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sol-Gel Technologies has higher revenue and earnings than Replimune Group. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	11.88	-$6.13M	-$0.34	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A

Replimune Group has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Replimune Group	N/A	-128.57%	-82.35%

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sol-Gel Technologies beats Replimune Group on 12 of the 16 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Esperion Therapeutics?

Sol-Gel Technologies (NASDAQ:SLGL) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Sol-Gel Technologies has higher earnings, but lower revenue than Esperion Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	11.88	-$6.13M	-$0.34	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Sol-Gel Technologies' net margin of -5.66%. Esperion Therapeutics' return on equity of -0.14% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Esperion Therapeutics	0.12%	-0.14%	0.12%

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 140.97%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 74.21%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sol-Gel Technologies had 16 more articles in the media than Esperion Therapeutics. MarketBeat recorded 17 mentions for Sol-Gel Technologies and 1 mentions for Esperion Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.90 beat Esperion Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sol-Gel Technologies beats Esperion Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$226.34M	$5.75B	$6.88B	$12.26B
Dividend Yield	N/A	0.71%	2.67%	9.79%
P/E Ratio	-241.05	8.74	26.99	23.71
Price / Sales	11.88	26.13	493.86	76.90
Price / Cash	N/A	7.97	50.54	59.64
Price / Book	10.01	4.10	10.28	6.07
Net Income	-$6.13M	$99.67M	$3.60B	$331.84M
7 Day Performance	-1.49%	-5.64%	-1.25%	-1.53%
1 Month Performance	12.78%	-3.26%	-0.35%	-2.46%
1 Year Performance	645.09%	94.85%	18.41%	13.66%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	4.3552 of 5 stars	$81.96 +1.8%	$197.50 +141.0%	+637.7%	$226.34M	$19.39M	N/A	50	News Coverage Analyst Revision
DRCT Direct Digital	1.3927 of 5 stars	$2.57 -0.4%	N/A	-97.9%	$1.90M	$34.69M	N/A	60	Positive News Short Interest Decrease
TRAW Traws Pharma	3.5506 of 5 stars	$0.70 +2.9%	$1.00 +41.9%	-70.1%	$10.68M	$2.79M	N/A	17	Positive News
AMPH Amphastar Pharmaceuticals	3.6135 of 5 stars	$18.81 -2.5%	$22.00 +17.0%	-16.8%	$829.33M	$719.89M	11.33	1,976	Analyst Upgrade
REPL Replimune Group	1.3085 of 5 stars	$9.87 -0.7%	$8.13 -17.7%	+212.9%	$828.49M	N/A	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, AMPH, REPL, and ESPR

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Summary

How does Sol-Gel Technologies compare to Amphastar Pharmaceuticals?

Summary

How does Sol-Gel Technologies compare to Replimune Group?

Summary

How does Sol-Gel Technologies compare to Esperion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, AMPH, REPL, and ESPR

How does Sol-Gel Technologies compare to Direct Digital?

Do insiders and institutionals hold more shares of DRCT or SLGL?

Do analysts prefer DRCT or SLGL?

Which has better earnings and valuation, DRCT or SLGL?

Does the media refer more to DRCT or SLGL?

Is DRCT or SLGL more profitable?

Which has more risk & volatility, DRCT or SLGL?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Does the media prefer TRAW or SLGL?

Do analysts prefer TRAW or SLGL?

Is TRAW or SLGL more profitable?

Do insiders & institutionals hold more shares of TRAW or SLGL?

Which has more volatility & risk, TRAW or SLGL?

Which has higher valuation and earnings, TRAW or SLGL?

Summary

How does Sol-Gel Technologies compare to Amphastar Pharmaceuticals?

Do institutionals and insiders believe in SLGL or AMPH?

Which has more risk and volatility, SLGL or AMPH?

Is SLGL or AMPH more profitable?

Which has better valuation & earnings, SLGL or AMPH?

Do analysts prefer SLGL or AMPH?

Does the media favor SLGL or AMPH?

Summary

How does Sol-Gel Technologies compare to Replimune Group?

Which has more risk and volatility, SLGL or REPL?

Does the media favor SLGL or REPL?

Do analysts recommend SLGL or REPL?

Which has better earnings & valuation, SLGL or REPL?

Is SLGL or REPL more profitable?

Do institutionals & insiders believe in SLGL or REPL?

Summary

How does Sol-Gel Technologies compare to Esperion Therapeutics?

Which has more volatility and risk, SLGL or ESPR?

Which has higher valuation & earnings, SLGL or ESPR?

Is SLGL or ESPR more profitable?

Do insiders & institutionals believe in SLGL or ESPR?

Do analysts recommend SLGL or ESPR?

Does the media favor SLGL or ESPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools